Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP11157819A	2014-06-11	Ahrens, Gabriele	Patent maintained as amended
EP02782151A	2013-06-12	Acino Pharma AG	Revoked
EP02782151A	2013-06-11	Germann, Sandra	Revoked
EP02801042A	2012-09-14	Ahrens, Gabriele	Patent maintained as amended
EP02801042A	2012-09-11	LTS LOHMANN Therapie-Systeme AG	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8603514	June, 2017	Terminated-Denied	MonoSol Rx, LLC	Dr. Reddy’s Laboratories, Inc.
US8603514	June, 2017	Terminated-Denied	MonoSol Rx, LLC	Par Pharmaceutical, Inc.
US8603514	November, 2016	Terminated-Adverse Judgment	MonoSol Rx, LLC	Mylan Technologies, Inc.
US8603514	May, 2016	Terminated-Denied	MonoSol Rx, LLC	Dr. Reddy's Laboratories, Inc.
US8603514	December, 2015	Terminated-Denied	MONOSOL RX LLC	Teva Pharmaceuticals USA Inc
US8765167	October, 2014	FWD Entered	MonoSol Rx, LLC.	BioDelivery Sciences International, Inc.
US8765167	October, 2014	Terminated-Denied	MonoSol Rx, LLC.	BioDelivery Sciences International, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167	AQUESTIVE	Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions	Feb, 2024 (2 months ago)
US8603514	AQUESTIVE	Uniform films for rapid dissolve dosage form incorporating taste-masking compositions	Apr, 2024 (23 days ago)

Exservan is owned by Aquestive.

Exservan contains Riluzole.

Exservan has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Exservan are:

Exservan was authorised for market use on 22 November, 2019.

Exservan is available in film;oral dosage forms.

The generics of Exservan are possible to be released after 03 April, 2024.

Market Authorisation Date: 22 November, 2019

Treatment: NA

Dosage: FILM;ORAL

Exservan patents expiration